Why the study?
Does oral AcSDKP ameliorate kidney fibrosis in mouse models of diabetic nephropathy?
Population
Two mouse models of diabetic nephropathy: streptozotocin- induced type 1 diabetic CD-1 mice and type 2…
Comparison
Oral N-acetyl-seryl-aspartyl-lysyl-proline alone… vs Imidapril alone or untreated control
Design
Preclinical
Key result
Oral administration of AcSDKP, alone or with imidapril, ameliorated glomerulosclerosis and tubulointerstitial fibrosis and restored plasma cystatin C levels in diabetic mice.
Authors
Loading...
Supports AcSDKP investigation in diabetic nephropathy; leaves open human translation and clinical utility.
Does oral AcSDKP ameliorate kidney fibrosis in mouse models of diabetic nephropathy?
Oral administration of the endogenous peptide AcSDKP ameliorates kidney fibrosis and restores antifibrotic microRNAs in mouse models of type 1 and type 2 diabetic nephropathy.
Nitta et al. (2016) studied Diabetic nephropathy. Oral AcSDKP vs. Imidapril alone or untreated was evaluated on Glomerulosclerosis, tubulointerstitial fibrosis, and plasma cystatin C levels. Oral administration of AcSDKP, alone or with imidapril, ameliorated glomerulosclerosis and tubulointerstitial fibrosis and restored plasma cystatin C levels in diabetic mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: